Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Kyverna Therapeutics

Main focus: Next-generation cell therapies for autoimmune diseases

Company stage: Pre-clinical

Diseases (gene editing): Autoimmune diseases

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Emeryville, CA, USA

Website:https://kyvernatx.com/

Pipeline:https://kyvernatx.com/the-science/

Gene editing partnerships: Intellia Therapeutics

Kyverna Therapeutics develops cellular therapies to treat autoimmune and inflammatory diseases. This includes both engineered regulatory T cells, CAR-T and SynNotch CAR-T cells. The company has licensed Intellia Therapeutics' CRISPR-Cas9 technology for the development of its allogeneic CD19-targeting CAR-T cell therapy.

Kyverna Therapeutics

Your Latest CMN News

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Scientists use CRISPR to develop new detection...

Scientists in China describe a sensitive and selective CRISPR-Cas12-based assay for the detection of a protein that is implicated in obesity and...

Company: Kyverna Therapeutics

Search CRISPR Medicine